---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-047994"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2024-11-27T23:59:59+00:00"
generated_at: "2026-05-29T13:27:40.544743+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum

## Summary
- Nasdaq letter on Nov 21, 2024: stockholders' equity fell below $2.5M required for continued listing.
- Company does not meet market value of listed securities or net income alternatives.
- Must submit compliance plan by Jan 6, 2025; Nasdaq may grant up to 180-day extension.
- If plan not accepted, Company may appeal to Nasdaq Hearings Panel.
- Stock continues trading under GTBP; no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001493152-24-047994
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2024-11-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315224047994/0001493152-24-047994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315224047994/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-047994
- JSON: https://secwatch.observer/filing/0001493152-24-047994.json
- Plain text: https://secwatch.observer/filing/0001493152-24-047994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.